Aquestive Therapeutics (AQST) PT Raised to $9.50 at Oppenheimer

September 27, 2022 12:55 PM EDT
Get Alerts AQST Hot Sheet
Price: $0.92 -1.08%

Rating Summary:
    8 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 5 | New: 0
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Oppenheimer analyst Francois Brisebois raised the price target on Aquestive Therapeutics (NASDAQ: AQST) to $9.50 (from $8.50) while maintaining an Outperform rating.

The analyst commented, "AQST recently reported positive results from its EPIPHAST II, comparing AQST-109 to EpiPen 0.3mg and epinephrine 0.3mg IM injection. PK/PD comparisons showed that AQST-109 demonstrated a much faster Tmax of 12mins, compared to EpiPen and 0.3mg IM, which is encouraging since fast systemic delivery of epinephrine is crucial during an anaphylaxis event. Comparable Cmax (IM and EpiPen) and PD (EpiPen) values were seen after single-dose administrations. Of note, AQST-109's safety profile was in line with expectations, with no SAEs reported. Given the size of epinephrine US market, and the unmet need (lack of prescriptions and refills), a convenient oral comparable option should be well-received, in our opinion. We are reiterating our Outperform rating and increasing our PT to $9.50 from $8.50."

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change